Pleura and Peritoneum (Jun 2022)

Pressurized intraperitoneal aerosol chemotherapy (PIPAC) in multimodal therapy for patients with oligometastatic peritoneal gastric cancer: a randomized multicenter phase III trial PIPAC VEROne

  • Casella Francesco,
  • Bencivenga Maria,
  • Rosati Riccardo,
  • Fumagalli Uberto Romario,
  • Marrelli Daniele,
  • Pacelli Fabio,
  • Macrì Antonio,
  • Donini Annibale,
  • Torroni Lorena,
  • Pavarana Michele,
  • De Manzoni Giovanni

DOI
https://doi.org/10.1515/pp-2022-0111
Journal volume & issue
Vol. 7, no. 3
pp. 135 – 141

Abstract

Read online

Peritoneal carcinomatosis is the most frequent site of metastases in patients with gastric cancer. Current standard treatment is palliative systemic chemotherapy with very poor prognosis. Cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) resulted in long-term benefits in selected patients. Among patients with peritoneal carcinomatosis, a distinctive subset is oligometastatic disease which is characterized by low metastatic burden. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) is a recent technique of intraperitoneal chemotherapy used in combination with systemic chemotherapy with promising results.

Keywords